Bolkar Sahinler, MD
Interventional Pain Medicine · Lubbock, TXNPI 1659368793
Payments from drug & device makers
Across 507 payments — averaging $371.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$173K
- Roche Diagnostics Corporation$5K
- Abbott$3K
- Relievant Medsystems, Inc.$2K
- Vertiflex, Inc.$2K
- Boston Scientific$989
- plus $3K from 26 others
What the payments were for
- Consulting fees$4,7002%
- Travel & lodging$5,1593%
- Food & beverage$14,2568%
- Entertainment$500%
- Other$164,28287%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 302 | $173,399 |
| Roche Diagnostics Corporation | 2 | $4,700 |
| Abbott | 46 | $3,304 |
| Relievant Medsystems, Inc. | 15 | $1,771 |
| Vertiflex, Inc. | 10 | $1,553 |
| Boston Scientific | 20 | $989 |
| AbbVie(2 entities) | 43 | $676 |
| Si-bone, Inc. | 7 | $411 |
| Collegium Pharmaceutical, Inc. | 22 | $357 |
| MML US, Inc. | 7 | $265 |
| Globus Medical | 1 | $172 |
| Foundation Fusion Solutions, LLC | 2 | $160 |
| Surgentec | 1 | $139 |
| Stryker | 2 | $73 |
| Johnson & Johnson | 3 | $69 |
| Pfizer | 4 | $45 |
| Saluda Medical Americas, Inc. | 1 | $40 |
| Vertex | 2 | $39 |
| Novartis | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Spinal Simplicity, LLC | 1 | $27 |
| Zyla Life Sciences, Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Nalu Medical, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| International Rehabilitative Sciences, Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$5,357
- PROCLAIM$2,364
- VANTA ADAPTIVESTIM$2,194
- Superion ISS$1,281
- INTELLIS ADAPTIVESTIM$1,064
- SYNCHROMEDII$488
- INTELLIS$260
- Senza$172
- ReActiv8$156
- iFuse Implant$146
- OSTEOCOOL RF ABLATION SYSTEM$140
- TiLink$139
- ION$139
- OSTEOCOOL RF ABLATION$111
How this compares
$188,447 in reported general payments places this provider in the 95th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,235 | $120,852 |
| NucyntaTapentadol Hcl | 33 | $46,491 |
| OxycontinOxycodone Hcl | 77 | $34,359 |
| Fentanyl | 272 | $25,193 |
| Xtampza ErOxycodone Myristate | 50 | $24,462 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 760 | $23,649 |
| Nucynta ErTapentadol Hcl | 19 | $17,124 |
| Morphine Sulfate ErMorphine Sulfate | 517 | $14,616 |
| Gabapentin | 879 | $13,008 |
| Pregabalin | 573 | $12,356 |
| Hydromorphone Hcl | 644 | $11,948 |
| MovantikNaloxegol Oxalate | 20 | $11,419 |
| LinzessLinaclotide | 19 | $11,228 |
| Hydrocodone-IbuprofenHydrocodone/Ibuprofen | 30 | $7,449 |
| Hysingla ErHydrocodone Bitartrate | 15 | $6,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Nucynta Er | $357 | $88,077102 claims |
| Redhill Biopharma Inc.Movantik | $18 | $11,41920 claims |
| AbbVieLinzess | $676 | $11,22819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Lubbock
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
- Ankur KhoslaShenandoah$511K
- Brian RichDecatur$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.